Press releases

15 October 2018 - Advicenne Receives Health Canada Clearance to Extend its Pivotal Phase III Trial of ADV7103 in Canada

4 October 2018 - Advicenne to present additional data on ADV7103 at the European Society for Paediatric Nephrology during its 51st Annual Meeting

25 September 2018 - Advicenne Prepares its Expansion with Highly Experienced Industry Professionals

20 September 2018 - Advicenne Reports First-Half 2018 Results and Confirms Outlook for 2018

12 September 2018 - Advicenne receives approval for Marketing Authorization for ADV6209 in Pediatric Moderate Sedation

11 September 2018 - Advicenne to host a conference call on September 12, 2018 at 6 pm to comment its recent development

5 September 2018 - Advicenne announces FDA clearance of IND to commence pivotal Phase 3 trial of ADV7103 for distal Renal Tubular Acidosis

2 July 2018 - Advicenne confirms ADV7103’ safety and efficacy after 24 months in the Phase III Extension Study

31 May 2018 - Advicenne Announces ADV7103 Poster Presentation at the 55th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress

15 May 2018 - Advicenne enters into partnership with the European Society for Paediatric Nephrology (ESPN) aiming to improve patient care for distal Renal Tubular Acidosis (dRTA) in Europe

4 May 2018 - Advicenne receives authorisation from French regulation authorities to initiate pivotal phase II/III trial of ADV7103 in Cystinuria

30 April 2018 - Advicenne publishes its annual financial report

10 April 2018 - Advicenne 2017 Financial Results and Operational Perspectives for 2018

12 February 2018 - Advicenne announces its financial calendar for 2018 and cash position as of December 31st, 2017

24 January 2018 - Advicenne appoints Linda Law, MD as US Vice President, Clinical Development and Medical Affairs

5 January 2018 - Partial exercise of over – allotment option

5 December 2017 - Success of the IPO

6 November 2017 - ADV7103: 6-month data presented at ASN

20 September 2017 - Advicenne to Present a Poster at the 9th EuPFI Conference on ADV7103, an Innovative age-adapted Product for distal Renal Tubular Acidosis

11 September 2017 - Advicenne Announces Positive Pivotal Phase III Clinical Data for ADV7103 in Adults and Children Suffering from distal Renal Tubular Acidosis

2 July 2017 - Advicenne Receives Orphan Drug Designation from the EU for ADV7103 for the Treatment of distal Renal Tubulopathy

21 June 2017 - Advicenne to Present Preliminary Phase III Clinical Data on ADV7103 at the Upcoming European Society of Paediatric Nephrology’s Annual Meeting

20 March 2017 - Advicenne Announces the Closing of a €16 Million Financing Round

1 September 2016 - Advicenne appoints Ludovic Robin as Chief Business & Strategy Officer

23 February 2016 - Advicenne Pharma sells its drug candidate ADV6209 for moderate sedation to the Swiss Primex Pharmaceuticals

23 April 2015 - French marketing authorization approval for Levidcen

20 February 2014 - Advicenne has signed a license agreement with Desitin, on a new anti-epileptic for the French market, Levidcen micro-granules